{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lutetium+Lu+177+Dotatate", "query": { "intervention": "Lutetium Lu 177 Dotatate" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 45, "total_pages": 5, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Lutetium+Lu+177+Dotatate&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-01T07:04:28.669Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05610826", "title": "Preoperative PRRT Versus Surgical Cytoreduction in Metastatic Pancreatic Neuroendocrine Tumors to the Liver", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Neuroendocrine Tumor", "Pancreas Cancer" ], "interventions": [ { "name": "cytoreductive surgery", "type": "PROCEDURE" }, { "name": "Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT)", "type": "DRUG" }, { "name": "Peptide receptor radionuclide therapy (PRRT)", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "University of Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2023-03-07", "completion_date": "2024-09-11", "has_results": false, "last_update_posted_date": "2024-10-26", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05610826" }, { "nct_id": "NCT05278208", "title": "Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "High Grade Glioma", "Meningioma", "Embryonal Tumor", "Medulloblastoma", "Anaplastic Ependymoma", "Recurrent Diffuse Intrinsic Pontine Glioma", "Recurrent Malignant Glioma", "Recurrent Medulloblastoma", "Recurrent Primary Central Nervous System Neoplasm", "Refractory Diffuse Intrinsic Pontine Glioma", "Refractory Malignant Glioma", "Refractory Medulloblastoma", "Refractory Primary Central Nervous System Neoplasm" ], "interventions": [ { "name": "LUTATHERA® (Lutetium Lu 177 dotatate)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nationwide Children's Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "39 Years", "sex": "ALL", "summary": "4 Years to 39 Years" }, "enrollment_count": 65, "start_date": "2022-11-21", "completion_date": "2033-11", "has_results": false, "last_update_posted_date": "2026-07-20", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 4, "location_summary": "Aurora, Colorado • Cincinnati, Ohio • Columbus, Ohio + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05278208" }, { "nct_id": "NCT03206060", "title": "Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pheochromocytoma", "Paraganglioma", "Neuroendocrine Tumors", "Neuroendocrine Neoplasms" ], "interventions": [ { "name": "Lu-177-DOTATATE", "type": "DRUG" }, { "name": "Ga-68-DOTATATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 130, "start_date": "2017-10-10", "completion_date": "2033-01-01", "has_results": false, "last_update_posted_date": "2026-08-25", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03206060" }, { "nct_id": "NCT06395402", "title": "177Lu-DOTATATE Modified Delivery Based on Individualized Dosimetry", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumors", "Neuroendocrine Tumor Grade 1", "Neuroendocrine Tumor Grade 2" ], "interventions": [ { "name": "Lutetium Lu 177 dotatate therapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 120, "start_date": "2024-05-03", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2025-07-22", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT06395402" }, { "nct_id": "NCT04665739", "title": "Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Lung Neuroendocrine Tumor", "Functioning Lung Neuroendocrine Tumor", "Locally Advanced Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Neoplasm", "Lung Neuroendocrine Tumor G1", "Lung Neuroendocrine Tumor G2", "Metastatic Lung Neuroendocrine Neoplasm", "Metastatic Lung Neuroendocrine Tumor", "Non-Functioning Lung Neuroendocrine Tumor", "Recurrent Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Neoplasm", "Unresectable Lung Neuroendocrine Tumor" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Everolimus", "type": "DRUG" }, { "name": "Fludeoxyglucose F-18", "type": "OTHER" }, { "name": "Lutetium Lu 177 Dotatate", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Single Photon Emission Computed Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2023-02-03", "completion_date": "2027-07-01", "has_results": false, "last_update_posted_date": "2026-09-17", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 29, "location_summary": "Birmingham, Alabama • Beverly Hills, California • Loma Linda, California + 24 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04665739" }, { "nct_id": "NCT03972488", "title": "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Gastro-enteropancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "Lutathera", "type": "DRUG" }, { "name": "30 mg Octreotide long acting repeatable (LAR) (Sandostatin LAR Depot)", "type": "DRUG" }, { "name": "2.5% Lys-Arg sterile amino acid solution", "type": "DRUG" }, { "name": "High dose 60 mg octreotide long-acting repeatable", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advanced Accelerator Applications", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 226, "start_date": "2020-01-08", "completion_date": "2027-10-29", "has_results": true, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Tampa, Florida • Iowa City, Iowa + 3 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972488" }, { "nct_id": "NCT05142696", "title": "A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Extensive Stage Small Cell Lung Cancer" ], "interventions": [ { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "[68Ga]Ga-DOTA-TATE", "type": "DRUG" }, { "name": "Carboplatin", "type": "OTHER" }, { "name": "Etoposide", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 55, "start_date": "2022-07-13", "completion_date": "2028-03-07", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 7, "location_summary": "Orlando, Florida • Athens, Georgia • Lexington, Kentucky + 4 more", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Athens", "state": "Georgia" }, { "city": "Lexington", "state": "Kentucky" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05142696" }, { "nct_id": "NCT06379217", "title": "NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Neuroendocrine Prostate Cancer" ], "interventions": [ { "name": "[68Ga]Ga-PSMA-11", "type": "DRUG" }, { "name": "[68Ga]GA-DOTA-TATE", "type": "DRUG" }, { "name": "[68Ga]Ga-NeoB", "type": "DRUG" }, { "name": "[177Lu]Lu-PSMA-617", "type": "DRUG" }, { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "[177Lu]Lu-NeoB", "type": "DRUG" }, { "name": "L-Lysine HCl-L-Arginine HCl, 2.5 %,", "type": "DRUG" }, { "name": "Gonadotropin-releasing hormone (GnRH) analogues", "type": "DRUG" }, { "name": "GnRH antagonists", "type": "DRUG" }, { "name": "Antiemetics & antinauseants", "type": "DRUG" }, { "name": "Metoclopramide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 31, "start_date": "2024-07-29", "completion_date": "2026-09-11", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 2, "location_summary": "Omaha, Nebraska • New York, New York", "locations": [ { "city": "Omaha", "state": "Nebraska" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06379217" }, { "nct_id": "NCT05109728", "title": "A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "[177Lu]Lu-DOTA-TATE", "type": "DRUG" }, { "name": "[68Ga]Ga-DOTA-TATE", "type": "DRUG" }, { "name": "Temozolomide", "type": "OTHER" }, { "name": "Radiotherapy", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 63, "start_date": "2022-05-10", "completion_date": "2027-05-24", "has_results": false, "last_update_posted_date": "2026-09-22", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 4, "location_summary": "New York, New York • Pittsburgh, Pennsylvania • Houston, Texas + 1 more", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05109728" }, { "nct_id": "NCT04544098", "title": "Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Neuroendocrine Tumors", "Liver-Dominant Metastatic Pancreatic Neuroendocrine Tumors" ], "interventions": [ { "name": "177Lu-DOTATATE", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2020-09-02", "completion_date": "2027-09", "has_results": false, "last_update_posted_date": "2026-05-07", "last_synced_at": "2026-10-01T07:04:28.669Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04544098" } ] }